Barclays PLC Spectrum Pharmaceuticals Inc Call Options Transaction History

Barclays PLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2020 Aug 12, 2020	SELL	$2.11 - $3.38 $13,504 - $21,632	-6,400 Reduced 88.89%	800 $3,000
Q1 2020 May 13, 2020	SELL	$1.83 - $3.45 $8,967 - $16,905	-4,900 Reduced 40.5%	7,200 $17,000
Q4 2019 Feb 10, 2020	BUY	$3.5 - $10.35 $40,250 - $119,025	11,500 Added 1916.67%	12,100 $44,000
Q1 2019 May 15, 2019	SELL	$9.08 - $11.84 $65,376 - $85,248	-7,200 Reduced 92.31%	600 $6,000
Q4 2018 Feb 14, 2019	SELL	$6.39 - $16.99 $578,295 - $1.54 Million	-90,500 Reduced 92.07%	7,800 $68,000
Q3 2018 Nov 14, 2018	BUY	$16.52 - $24.82 $1.25 Million - $1.88 Million	75,900 Added 338.84%	98,300 $1.65 Million
Q2 2018 Aug 14, 2018	BUY	$14.31 - $21.75 $240,408 - $365,400	16,800 Added 300.0%	22,400 $469,000
Q1 2018 May 15, 2018	SELL	$16.09 - $23.07 $16,090 - $23,070	-1,000 Reduced 15.15%	5,600 $90,000
Q4 2017 Feb 14, 2018	BUY	$13.36 - $20.73 $36,072 - $55,971	2,700 Added 69.23%	6,600 $125,000
Q3 2017 Nov 14, 2017	BUY	$8.75 - $14.07 $34,125 - $54,873	3,900	3,900 $55,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.